Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Canakinumab

EU orphan designation number: EU/3/12/1071   
Active ingredient: Canakinumab
Indication: Treatment of tumour necrosis factor receptor-associated periodic syndrome
Sponsor: Novartis Europharm Limited
Frimley Business Park, Camberley GU16 7SR, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/11/2012 Centralised Orphan - Designation EMA/OD/060/12 (2012)8204 of 08/11/2012
29/08/2014 Centralised Orphan - Change of address